Presentations in this session:

12:30 TuPp0301    Abstract Patterns of HIV-1 genotypic antiretroviral resistance in clinical practice: a survey of the Brazilian Network for Genotypic Resistance Munerato P.1, Andreo S.M.1, Sucupira M.C.1, Mamede S.2, Mota G.1, Sá Filho D.1, Cavalieri E.1, Arakaki D.2, Marins J.R.P.2, Diaz R.S.1 1UNIFESP, São Paulo, Brazil, 2Coordenação Nacional DST/AIDS, Brasília, Brazil

12:35 TuPp0302    Abstract HIV-1 drug resistance in China: nation-wide survey and analysis of impacting factors in the national ARV treatment program Xing H.1, Jiang S.1, Si X.1, Cheng H.1, Shang H.2, Li J.3, Kang L.4, Zhong P.4, Shao Y.1 1National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China, 2China Medical University, Shenyang, China, 3Chinese Academy of Military Medical Sciences, Beijing, China, 4Shanghai Center for Disease Control and Prevention, Shanghai, China

12:40 TuPp0303    Abstract The presence of a single canonical NNRTI resistance mutation in naïve HIV-1 infected patients reduces the proportion achieving virological success when starting NNRTI-based regimens. Price H.1, Jones R.1, Mandalia S.1, Bower M.1, Nelson M.1, Gazzard B.1 1Chelsea & Westminster Hospital, London, United Kingdom

12:45 TuPp0304    Abstract HIV-proviral DNA and plasma-RNA sequencing for detection of drug resistance mutations in antiretroviral naive patients Parisi S.G.1, Mazzi R.2, Zazzi M.3, Manfrin V.4, Nicolini G.5, Carolo G.6, Boldrin C.1, Franchin E.1, Dal Bello F.1, Gatti F.2, Palù G.1 1University Hospital, Padua, Italy, 2Hospital, Verona, Italy, 3University Hospital, Siena, Italy, 4Hospital, Vicenza, Italy, 5Hospital, Schio, Italy, 6Hospital, Legnago, Italy

12:50 TuPp0305    Abstract Lack of resistance to tenofovir at week 48 and impact of baseline resistance mutations on treatment response in study 934 McColl D.1, Margot N.1, Lu B.1, Cheng A.1, Miller M.1 1Gilead Sciences, Inc., Foster City, United States of America

12:55 TuPp0306    Abstract High rate of virological failure during once daily therapy with tenofovir + didanosine 250mg + efavirenz in antiretroviral naive patients – Results of the 12 week interim analysis of the TEDDI trial van Lunzen J.1, Schewe K.2, Kuhlmann B.3, Hoffmann C.4, Stoll M.5, Dellamonica P.6, Prazuck T.7, Benech H.8, Taburet A.M.9, Delfraissy J.F.9 1University Medical Center Eppendorf, Hamburg, Germany, 2Private Practice St. Georg, Hamburg, Germany, 3Private Practice, Hannover, Germany, 4University of Schleswig-Holstein Campus Kiel, Kiel, Germany, 5University Medical School, Hannover, Germany, 6CHU, Nice, France, 7CHR, Orleans, France, 8CEA, Gif-sur-Yvette, France, 9CHU Bicetre, Paris, France